Correction addresses errors in cost effectiveness analysis tables for atezolizumab in small cell lung cancer, emphasizing accuracy in data presentation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: